Abstract
Biomarkers in the clinical oncology field can have tremendous therapeutic impact especially if the marker is detected before clinical symptoms. This impact can be extended to the evaluation of clinical oncology treatments allowing evaluation of potential compounds to determine their efficacy in the disease treatment. The discovery of clinical biomarkers can consume time, resources and costs. Therefore, it is important that the most effective strategies are employed to discover these biomarkers. These strategies may include the integration of available genomic, proteomic and histopathological technologies, which could reduce the costs and aid in the validation of the biomarker. Certainly the type of biomarker needed to address a particularly defined problem will drive the type of technology. However, a single biomarker to diagnose a specific cancer can be as elusive as relying on a single technology. This review examines some of the technologies used to discover biomarkers and presents the use of combinatorial technical synergies to discover and validate potential clinical oncology biomarkers.
Keywords: biomarker, oncology, integration, functional informatics, proteomics, genomics, histology
Current Topics in Medicinal Chemistry
Title: Synergistic Approaches to Clinical Oncology Biomarker Discovery
Volume: 5 Issue: 11
Author(s): Stanley M. Belkowski, Deborah Polkovitch and Michael R. D'Andrea
Affiliation:
Keywords: biomarker, oncology, integration, functional informatics, proteomics, genomics, histology
Abstract: Biomarkers in the clinical oncology field can have tremendous therapeutic impact especially if the marker is detected before clinical symptoms. This impact can be extended to the evaluation of clinical oncology treatments allowing evaluation of potential compounds to determine their efficacy in the disease treatment. The discovery of clinical biomarkers can consume time, resources and costs. Therefore, it is important that the most effective strategies are employed to discover these biomarkers. These strategies may include the integration of available genomic, proteomic and histopathological technologies, which could reduce the costs and aid in the validation of the biomarker. Certainly the type of biomarker needed to address a particularly defined problem will drive the type of technology. However, a single biomarker to diagnose a specific cancer can be as elusive as relying on a single technology. This review examines some of the technologies used to discover biomarkers and presents the use of combinatorial technical synergies to discover and validate potential clinical oncology biomarkers.
Export Options
About this article
Cite this article as:
Belkowski M. Stanley, Polkovitch Deborah and D'Andrea R. Michael, Synergistic Approaches to Clinical Oncology Biomarker Discovery, Current Topics in Medicinal Chemistry 2005; 5 (11) . https://dx.doi.org/10.2174/156802605774297074
DOI https://dx.doi.org/10.2174/156802605774297074 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
Addressing the Most Common Causes of Death with Niacin/NAD and Inositol Polyphosphates
The most common causes of death in the world are cardiovascular disease (CVD) and cancer. These are perhaps best addressed by reducing lipodystrophy and blockages with niacin and inositol polyphosphates (e.g., IP6+inositol) respectively when addressing CVD. Niacin serves as a vitamin by virtue of its role as a skeletal precursor ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
What Have We Learned from the Novel Human Cytochromes P450 Hidden in the Databases?
Current Genomics Oncogenic MicroRNAs in the Genesis of Leukemia and Lymphoma
Current Pharmaceutical Design Trebananib (AMG 386): A Non-VEGF Antiangiogenesis Option in Women with Ovarian Cancer
Current Angiogenesis (Discontinued) The Impacts of Non-coding RNAs and N<sup>6</sup>-Methyladenosine on Cancer: Past, Present and Future
Current Cancer Drug Targets Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy
Mini-Reviews in Medicinal Chemistry Current Remedial Strategies for the Treatment of Rheumatoid Arthritis through the Oral Route with Janus Kinase Inhibitors
Drug Delivery Letters What we have Learned from Animal Models of Mycoplasma pneumoniae Disease: Virulence Mechanisms and Host Responses
Current Pediatric Reviews Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Terpyridines and their Complexes with First Row Transition Metal Ions:Cytotoxicity, Nuclease Activity and Self-Assembly of Biomacromolecules
Current Topics in Medicinal Chemistry Quantitative Comparisons of Deep-learning-based and Atlas-based Auto- segmentation of the Intermediate Risk Clinical Target Volume for Nasopharyngeal Carcinoma
Current Medical Imaging Wzy-Dependent Bacterial Capsules as Potential Drug Targets
Current Drug Targets Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets Different Methods for Molecular and Rapid Detection of Human Novel Coronavirus
Current Pharmaceutical Design An Artificial Neural Network Model for Predicting the Subcellular Localization of Photosensitisers for Photodynamic Therapy of Solid Tumours
Current Medicinal Chemistry Ultrasound-based Radiomics for Predicting Metastasis in the Lymph Nodes Posterior to the Right Recurrent Laryngeal Nerve in Patients with Papillary Thyroid Cancer
Current Medical Imaging Macromolecular Prodrugs Based on Synthetic Polyaminoacids: Drug Delivery and Drug Targeting in Antitumor Therapy
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
The Natural Products Journal Combination of Cefotaxime and Cisplatin Specifically and Selectively Enhances Anticancer Efficacy in Nasopharyngeal Carcinoma
Current Cancer Drug Targets Tumor Initiating Cells
Current Pharmaceutical Biotechnology